ImmunityBio/$IBRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ImmunityBio
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Ticker
$IBRX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
671
ISIN
US45256X1037
Website
ImmunityBio Metrics
BasicAdvanced
$2.5B
-
-$0.58
-0.07
-
Price and volume
Market cap
$2.5B
Beta
-0.07
52-week high
$7.63
52-week low
$1.83
Average daily volume
11M
Financial strength
Current ratio
2.219
Quick ratio
1.606
Long term debt to equity
-138.04
Total debt to equity
-139.303
Interest coverage (TTM)
-2.15%
Profitability
EBITDA (TTM)
-296.588
Gross margin (TTM)
99.81%
Net profit margin (TTM)
-1,310.30%
Operating margin (TTM)
-1,003.83%
Effective tax rate (TTM)
0.06%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-55.61%
Return on equity (TTM)
63.86%
Valuation
Price to revenue (TTM)
67.531
Price to book
-4.1
Price to tangible book (TTM)
-3.99
Price to free cash flow (TTM)
-5.594
Free cash flow yield (TTM)
-17.88%
Free cash flow per share (TTM)
-50.77%
Growth
Revenue change (TTM)
10,238.41%
Earnings per share change (TTM)
-45.68%
3-year revenue growth (CAGR)
237.94%
3-year earnings per share growth (CAGR)
-15.15%
What the Analysts think about ImmunityBio
Analyst ratings (Buy, Hold, Sell) for ImmunityBio stock.
Bulls say / Bears say
ImmunityBio's ANKTIVA® has secured coverage from over a dozen insurance plans, representing more than 100 million lives within three months of FDA approval, indicating strong market acceptance. (stocktitan.net)
BTIG Research initiated coverage of ImmunityBio with a 'Buy' rating and a $6.00 price target, suggesting a potential upside of approximately 147.93% from the current price. (nasdaq.com)
ImmunityBio has received FDA authorization for an expanded access program to provide recombinant BCG (rBCG), addressing the critical shortage of TICE® BCG for bladder cancer treatment in the U.S., potentially capturing significant market share. (stocktitan.net)
ImmunityBio reported a net loss of $85.7 million in Q3 2024, with rising R&D and SG&A costs driven by the company's growth, indicating ongoing financial challenges. (finviz.com)
The company's total revenue for the trailing twelve months is $7.33 million, while its net income is a loss of $587.79 million, reflecting significant financial instability. (weissratings.com)
ImmunityBio's stock has experienced a 52-week low of $2.50 and a high of $10.53, indicating high volatility and potential risk for investors. (weissratings.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
ImmunityBio Financial Performance
Revenues and expenses
ImmunityBio Earnings Performance
Company profitability
ImmunityBio News
AllArticlesVideos
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
Business Wire·2 weeks ago
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
Business Wire·1 month ago
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug
Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImmunityBio stock?
ImmunityBio (IBRX) has a market cap of $2.5B as of June 20, 2025.
What is the P/E ratio for ImmunityBio stock?
The price to earnings (P/E) ratio for ImmunityBio (IBRX) stock is 0 as of June 20, 2025.
Does ImmunityBio stock pay dividends?
No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next ImmunityBio dividend payment date?
ImmunityBio (IBRX) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunityBio?
ImmunityBio (IBRX) has a beta rating of -0.07. This means that it has an inverse relation to market volatility.